-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2830 Adjunction of a Fish Oil Emulsion to Cytarabine and Daunorubicin Induction Chemotherapy in High-Risk AML. the Famyly Pilot Study from the French Innovative Leukemia Organization (FILO)

Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
Hematology Disease Topics & Pathways:
AML, Diseases, Therapies, Combinations, Myeloid Malignancies
Monday, December 7, 2020, 7:00 AM-3:30 PM

Emmanuel Gyan, MD, PhD1,2, Arnaud Pigneux, MD, PhD3*, Hunault-Berger Mathilde, MD, PhD4,5*, Pierre Peterlin, MD6,7*, Martin Carre, MD8*, Jacques-Olivier Bay, MD, PhD9,10, Caroline Bonmati, MD11*, Maria Pilar Gallego Hernanz12*, Bruno Lioure, MD13*, Philippe Bertrand, MD, PhD14*, Nicolas Vallet, MD15*, David Ternant, PharmD, PhD16*, François Darrouzain, PharmD, PhD17*, Frederic Picou, PhD2,18*, Marie C Bene, PharmSci, PhD7*, Christian Recher, MD, PhD19 and Olivier Herault, MD, PhD2,20

1CHU de Tours - Hôpital Bretonneau, Tours, France
2CNRS ERL 7001 LNOx "Leukemic Niche & Redox Metabolism", Tours, France
3Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
4department of hematology, CHU Angers, Angers, ML, France
5CRCINA Centre Hospitalier Universitaire d'Angers, Angers, France
6Clinical Hematology, HOPITAL HOTEL DIEU ET HME, NANTES CEDEX 1, France
7CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France
8Hematology, CHU Grenoble Alpes, La Tronche, France
9University of Auvergne, EA7453, CIC501, Clermont-Ferrand, France
10Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite d'Auvergne, EA7453, CIC501, Clermont-Ferrand, France
11Service D'Hématologie, Centre Hospitalier Universitaire De Nancy, Nancy, FRA
12Cllinical Hematology, Poitiers University Hospital, Poitiers, France
13Département d'Hématologie et d'Oncologie, CHU Strasbourg, Strasbourg, FRA
14Faculté de Médecine de Tours, Laboratoire de Biostatistiques, Tours, France
15Department of Hematology and Cellular Therapy, Tours University Hospital, UMR CNRS, François Rabelais University, Tours, France
16Université FrançOis Rabelais De Tours, Tours Cedex 9, FRA
17Laboratoire de Pharmacologie-Toxicologie, Centre hospitalier universitaire de Tours, Tours, France
18CNRS UMR 7292, LNOx team, Tours, France
19Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
20Service d'Hématologie Biologique, Centre Hospitalier Universitaire, Tours, France

Background. Acute myeloid leukemia (AML) with unfavorable cytogenetics remains a therapeutic challenge. We previously established that ex vivo exposure of AML blasts to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or fish oil emulsion (FO) induces Nrf2 pathway activation, metabolic switch and cell death (Picou et al., Pharmacol Res 2018;136:45–55).

Objectives. The FILO group launched a pilot clinical study to evaluate the feasibility, safety and efficacy of the adjunction of a commercial FO emulsion (OMEGAVEN) to 3+7 in untreated AML with unfavorable cytogenetics.

Patients and methods. The FAMYLY trial was a multicenter single-arm phase II study. Eligible patients had a diagnosis of untreated AML with unfavorable cytogenetics, 18 years old or above. For patients with WBC < 30 G/L, FO was administered at 2 mL/kg/d IV 2 days before 3+7 induction chemotherapy (daunorubicin 60 mg/m² days 1-3 and cytarabine 200 mg/m²/d as a continuous infusion days 1-7), until day 7 of induction. For patients with WBC >= 30 G/L, FO and 3+7 were started concomitantly, and FO was administered until day 9. The primary objective was complete response (CR) on the BM aspirate at the end of induction. Data from 75 patients with adverse cytogenetics and treated with daunorubicin and cytarabine in LAM2001 study (Lioure et al., Blood 2012) was used as a historical control. Serial blood samples were collected before treatment, and on days 1 and 3 after start of treatment, to evaluate the expression of NRF-2 target genes and antioxidant enzymes by RT-qPCR.

Results. Thirty patients were included. The median age was 54 years (range: 30-64 years), and only 3 patients were hyperleukocytic. FO administration raised the plasma levels of EPA and DHA (p<0.05). The Cmax of daunorubicin was 92.2 µg/L (Q1; Q3: 44.8; 105.1), and the AUC 414.9 ng.h, representing a mean clearance Cl=358.5 mL/h and a half-life T1/2=3.5h. The cytarabine clearance was highly variable with a mean of 1.628 L/h. A historical comparison to the LAM2001 trial found no unexpected toxicity. The CR rate was 76%, similar to the daunorubicin arm of the previous study in patients with unfavorable cytogenetics (72%). No survival improvement was observed in a historical comparison. RT-qPCR analysis of NRF-2 target genes and antioxidant enzymes (particularly HMOX1 and NQO1) in sequential blood samples did not show a significant in vivo response.

Conclusions. Altogether, FO emulsion adjunction to 3+7 is feasible and safe. Although CR rate improvement was not shown in this cohort of high-risk patients, further research aiming at finding the sufficient dose to trigger an NRF-2 response in vivo should be considered.

ClinicalTrials.gov identifier: NCT01999413.

Disclosures: No relevant conflicts of interest to declare.

OffLabel Disclosure: OMEGAVEN (fish oil emulsion) in Acute Myeloid Leukemia

*signifies non-member of ASH